Document is current

Article History

Received: 25 October 2021

Accepted: 21 December 2021

First Online: 7 January 2022

Declarations

:

: The study received approval from the ethics committee Northwest and Central Switzerland (reference no. BASEC Nr Req-2018-0120) and the ‘Comité National de Bioéthique du Tchad’ (CNBT) in N’Djamena, Chad (reference no. 134/PR/MESRI/SG/CNBT/2018). Research authorization was granted by the Chadian Ministry of Health and its ‘Direction de la Lutte contre la Maladie et de la Promotion de la Santé’ (reference no. 007/PR/MSP/DG/DLMPS/2018). Upon arrival in the study villages, an assembly was organized with the community representatives to discuss the study objectives and procedures. The traditional leaders, together with the local authorities, discussed the study and decided about concrete participation. Once a collective decision had been reached, written informed consent was obtained from the community representatives. In line with high illiteracy rates among the general population, individual participants consented orally. These consent procedures had received approval by the respective ethics committees. Those participants with a positive test result from either filtration or POC-CCA testing were invited to the health centre/health post and were administered praziquantel in the adequate dose (40 mg/kg) by the study nurse.

: All authors approved submission for publication of this manuscript.

: The authors declare that they have no competing interests.